Guanhao Biotech (300238.SZ): As of July 19th, the total number of shareholders in the company is 31,960.

Guanhao Biotech (300238.SZ) stated on the investor interactive platform on July 22nd that as of July 19, 2024, the total number of shareholders in the company was 31,960.

Gelonghui FinanceJul 22 04:17 ET

As of July 10th, 2024, the total number of shareholders for guanhao biotech (300238.SZ) was 32,054.

Guanhao Biotech (300238.SZ) stated on the investor interaction platform that as of July 10, 2024, the total number of shareholders of the company is 32,054.

Gelonghui FinanceJul 17 04:49 ET

Guanhao biotech (300238.SZ): the Phase III clinical trial of Benvimode cream for atopic dermatitis is still progressing in an orderly manner.

On July 12th, Gelonhui reported that an investor asked Guanhao Biotech (300238.SZ) on the interactive platform for investors, 'The new indication of pemodermatitis for Bemovate has been in Phase III clinical stage for a long time, please elaborate on the current progress.' The company replied that the Phase III clinical trial of Bemovate cream for special pemodermatitis is still progressing orderly. Please pay attention to the company's announcement for follow-up progress.

Gelonghui FinanceJul 12 03:49 ET

AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.

Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.

wallstreetcnJul 1 22:02 ET

Guanhao Biology (300238.SZ): Does not involve synthetic biology business or related research

Gelonghui May 9 丨 Guanhao Biology (300238.SZ) announced the stock price change announcement. The company paid attention to some media, stock bars and other platforms to discuss synthetic biology and related hot concepts. Currently, the company is not involved in synthetic biology business or related research.

Gelonghui FinanceMay 9 04:34 ET

Guanhao Biology (300238.SZ): The core business is the three major business segments of materials, pharmaceuticals, and cells

Gelonghui, May 8 | Guanhao Biology (300238.SZ) said on the investor interactive platform that the company's core business is the three major business segments: materials, pharmaceuticals, and cells. The main products in the field of materials include biotype dural (spine) membrane patches, B-type cerebral (spine) membrane patches, thoracic surgical repair films, sterile biological wound protection films, and Ario breast patches, which can be widely used in neurosurgery, thoracic surgery, dermatology, orthopedics, plastic surgery, etc. Benvermide, the main product in the pharmaceutical industry, can treat inflammatory and autoimmune diseases such as psoriasis and atopic dermatitis. The cell field mainly includes cell storage and cellular cartilage treatment

Gelonghui FinanceMay 8 04:20 ET